| Identification | Back Directory | [Name]
5-[1-(4-Fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-4-pyrimidinamine | [CAS]
1356053-63-8 | [Synonyms]
5-[1-(4-Fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-4-pyrimidinamine | [Molecular Formula]
C16H11FN6 | [MOL File]
1356053-63-8.mol | [Molecular Weight]
306.3 |
| Hazard Information | Back Directory | [Uses]
BMS-737 (compound 33) is a non-steroidal, reversible small molecule inhibitor. BMS-737 exhibits 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase. BMS-737 is designed to inhibit castration-resistant prostate cancer (CRPC) and significantly reduces testosterone levels without significant effects on orrodermal hormone and glucocorticoid levels[1]. | [References]
[1] Padmakar Darne C, et al. The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer. Bioorg Med Chem Lett. 2022 Nov 1;75:128951. DOI:10.1016/j.bmcl.2022.128951 |
|
|